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Summary The milk fat globule membrane antibodies HMFGI, HMFG2, NCRC 11 and four of the Mam 6
series, and the lectins peanut agglutinin, wheat germ agglutinin, Concanavalin A, Lotus tetragonolobus and
Ulex europaeus I have been applied to 115 stage I and II breast carcinomas (median follow up = 36 months) to
assess their value as prognostic markers. Of the milk fat globule membrane antibodies only NCRC 11 staining
showed a relationship to development of recurrent disease and overall survival, but this did not act as an
independent indicator over and above that provided by histological grade. None ofthe lectins gave prognostic
information, including those whose binding related to node status or grade. It is concluded that for short-term
prognosis none of the markers-can given independent prognostic information over and above that provided by
histological evaluation.
The biological behaviour of breast carcinoma can vary con-
siderably such that there are patients with a very poor prog-
nosis (Blamey et al., 1979) and those who remain free from
disease for over 20 years (Brinkley & Haybittle, 1975). Fac-
tors such as the extent of spread (both nodal and distant) at
the time of presentation are important in predicting
behaviour, and this forms the basis of staging systems. How-
ever, changes in surgical practice with a reduction in axillary
node sampling, plus a need to subdivide node negative early
stage patients into poor or good risk categories means that
there is a need to maximise the amount ofprognostic inform-
ation which can be obtained from the primary tumour.
The immunohistochemical assessment of primary tumours
for the expression of various markers of potential prognostic
value is one such approach. The use ofantibodies to different
components ofthe milk fat globule membrane has resulted in
conflicting reports. Wilkinson et al. (1984) concluded that the
antibody HMFG1 could be useful as a prognostic indicator,
but Berry et al. (1985) found no relationship between the
extent of staining with HMFG1 and HMFG2 and survival.
Ellis et al. (1985, 1987) used the monoclonal antibody NCRC
11, which although raised against a breast carcinoma meta-
stasis detects high molecular weight glycoproteins similar- to
those recognised by antibodies raised against the milk fat
globule membrane. They found a clear relationship between
immunoreactivity ofcarcinomas and the clinical course ofthe
disease. Angus et al. (1986), however, using the same
antibody, did not find a statistically significant relationship
with prognosis. Direct comparison of the staining obtained
with HMFG1, HMFG2 and NCRC 11 antibodies for the
same group ofcarcinomas and their relationship to prognosis
has not been published.
Another approach which has-been evaluated for its prog-
nostic value has been the binding of lectins to primary
tumours. Greater reactivity of carcinomas with Helix
pomatia was reported as relating to poorer survival (Fenlon
et al., 1987; Leathem & Brooks, 1987) as did Ulex europaeus I
binding (Fenlon et al., 1987).
In the present study a group of early (stage I and II)
carcinomas have been studied for the expression of milk fat
globule membrane antigens as determined by antibodies
HMFG1, HMFG2, NCRC 11 and four against the Mam 6
antigen (Hilkens et al., 1984), and for binding of the lectins
Concanavalin A, peanut agglutinin, wheat germ agglutinin,
Lotus tetragonolobus and Ulex europaeus I (Walker, 1983,
1984a,b, 1985), and the findings related to short-term recur-
rence and survival.
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Materials and methods
Patients
Primary breast carcinomas excised from 115 patients between
May 1981 and June 1986 were studied. Criteria for inclusion
were: knowledge of lymph node status; tumour less than
5 cm in size; no clinical or pathological evidence of skin or
muscle infiltration; no evidence of distant metastasis; no
previous history of breast carcinoma and no subsequent
development of a second primary tumour.
The primary treatment for the majority -of patients was
mastectomy with axillary dissection. A small number under-
went lumpectomy and radiotherapy, with axiilary node samp-
ling. All patients with axillary lymph node metastasis
received a course of radiotherapy. A small number (< 10)
were given adjuvant chemotherapy. Clinical follow-up was
from 12 to 82 months with a median follow-up period of 36
months.
Tissues and histology
All cases were received immediately after resection. Samples
from each were frozen in isopentane cooled in liquid nitro-
gen, and stored in liquid nitrogen vapour phase. A parallel
block was fixed in 4% formaldehyde in saline for 18-36 h
and processed through to paraffin wax.
Haematoxylin and eosin stained sections were examined
for classification using WHO criteria, and graded for
differentiation using a modification of the Broom & Richard-
son grading system (Elston, 1987).
Immunohistochemistry
The mouse monoclonal antibodies HMFGI and HMFG2
were purchased from Oxoid Ltd. HMFG2 was also received
as a gift from Dr J. Taylor-Papadimitriou. NCRC 11 was a
gift of Dr I.O. Ellis, and the Mam 6 antibodies (115 D8, 115
F5, 139 H2 and 140 Cl) a gift of Dr J. Hilkens.
Sections (4#im) were cut from each formalin-fixed,
paraffin-embedded block. For all antibodies parallel sections
were incubated with 0.1% trypsin (Difco 1:250) in 0.12%
calcium chloride pH 7.8 at 37°C for 30 min or buffer. After
washing the antibodies were applied to both trypsinised and
non-trypsinised sections diluted in Tris-buffered saline pH 7.6
as follows: HMFG1, 1:10; HMFG2, 1:10; NCRC 11, 1:10;
Mam 6 series, 1:100. The sections were incubated at 4°C for
18 h, followed by rinsing and washing in Tris-buffered saline.
Peroxidase conjugated rabbit anti mouse immunoglobulin
antiserum (Dako Ltd) was applied for 30 min. After rinsing
and washing the peroxidase was localised by the
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diaminobenzidine-hydrogen peroxide reaction, and the nuclei
counterstained with Mayer's haematoxylin.
Controls were the omission of the primary antibody.
Lectin histochemistry
The methods for this have been described previously
(Walker, 1983, 1984a,b, 1985). All lectins were obtained from
Sigma Chemical Company. Briefly, Concanavalin A-FITC
(10fLg ml-') was applied to trypsinised and non-trypsinised
4tLm formalin-fixed, paraffin-embedded sections, and the
staining examined using a fluorescent microscope. Wheat
germ agglutinin-peroxidase (5figml-') was incubated with
formalin-fixed, paraffin-embedded sections for 60 min and the
peroxidase localised as for the immunohistochemical method.
Serial formalin-fixed, paraffin-embedded sections were
incubated with either acetate buffer (pH 5.5) for 18 h at 37°C
or neuraminidase (Koch-Light) under the same conditions,
before application of peanut lectin-peroxidase (10jigml-').
Development was as above. Frozen sections (6-8ptm) from
each case were incubated with Ulex europaeus I-peroxidase
(10 tAg ml-,) and Lotus tetragonolobus-peroxidase
(30yg ml-') for 60 min, followed by development of the
peroxidase.
Controls for each lectin were absorption with 0.1 M appro-
priate and inappropriate sugars.
Assessment
Antibodies The proportion of cells reacting with HMFGI
and HMFG2 was quantified by cell counting, fields being
selected at random but with representative assessment of the
whole section. The extent of staining was divided into four
categories: negative; less than 30% (few); 30-60%
(moderate); more than 60% (many). In general, counts were
less than 20%, between 40 and 50% and clearly above 60%.
For a group of 30 carcinomas cell counting was repeated
using a Kontron Messgerte GMBH Videoplan, as described
previously (Jones & Walker, 1987), and good reproducibility
was demonstrated. Localisation of staining, e.g. extra or
intracellular, and intensity of staining were not assessed.
A similar method was used for assessing NCRC 11 and
Mam 6 staining, but the extent of staining was categorised
as: negative; less than 25%; 25-50%; 50-75%; and greater
than 75%. Intra-observer variation was assessed by perform-
ing a second assessment at least four months after the first
one, and without knowledge of the first score, and was found
to be less than 5%.
Lectins Assessment was as described previously (Walker
1983, 1984a,b, 1985). This was as follows.
Concanavalin A - the predominant intracellular site of
staining was considered and not the extent or intensity. The
categories were peripheral, cytoplasmic and combined
peripheral and cytoplasmic.
Peanut agglutinin - the extent of reactivity before and after
neuraminidase treatment was assessed and divided into four
categories: little reactivity before neuraminidase/majority of
cells react after (few/many); little reactivity before
neuraminidase/staining of 25-75% cells after (few/
moderate); staining of 25-75% of cells before neuramini-
dase/staining of greater than 75% of cells after enzyme
(moderate/many); little reactivity without or with
neuraminidase treatmnt (few/few).
Wheat germ agglutinin, Lotus tetragonolobus agglutinin,
Ulex europeus I agglutinin - greater than 75% of cells stain-
ing (many); 25-75% of cells staining (moderate); less than
25% of cells reacting (few); negative.
Statistics
The relationship between the staining pattern for all markers
and grade and node status was assessed using x2 tests.
Univariate analysis of the relationship of all markers, grade
and node status to recurrence and survival was performed
using x2 tests and life table analysis. Cox regression analysis
was used to test associations between staining and recurrence
and survival, after adjustment for grade and node status.
Results
Clinico-pathologicalfindings
There were 55 patients with evidence of lymph node meta-
stasis and 60 who were node negative. Classification of the
carcinomas resulted in: infiltrating duct, 91; infiltrating
lobular, 17; mucinous, four; tubular, two; medullary, one.
There were 17 well differentiated (grade I) carcinomas, 56
moderately differentiated (grade II) and 42 poorly
differentiated (grade III) tumours.
During the period offollow-up 25 patients had died, and a
further 12 patients developed recurrent disease.
Frequency ofstaining and relationship to node status andgrade
The frequency of the extent of staining with the milk fat
globule membrane antibodies is shown in Table I, and for
the lectin binding in Table II.
TableII Extentofbindingoflectinstobreastcarcinomas,expressedas
percentages
WGA (%) LTA (%) UEA (%)
Many 47 17 29
Moderate 41 33 19
Few 12 32 35
Negative 0 18 17
PNA (%) ConA (%)
few/many 47 peripheral 29
few/moderate 27 peripheral + 43.5
cytoplasmic
moderate/many 12
few/few 14 cytoplasmic 27.5
WGA =wheat germ agglutinin; LTA = Lotus tetragonolobus;
UEA = Ulex europaeus I; PNA = peanut agglutinin; ConA=
Concanavalin A.
Table I Frequency of staining with milk fat globule membrane antibodies
Assessment HMFGJ (%) HMFG2 (%)
Many 13 54
Moderate 33 36.5
Few 39 9.5
Negative 15 0
NCRC (%) 15D8 (%) 15F5 (%) 139H2 (%) 140CI (%)
> 75 34 59 43 74 46
50-75 36.5 25 18 24 30
25-50 8 10 19 2 9
<25 21.5 6 20 0 15
For methods of assessment see text.464 R.A. WALKER
It was evident that there were quite marked variations in
the extent of reactivity with the milk fat globule membrane
antibodies, both within individual tumours and overall. Only
the two fucose-specific lectins could be compared, and the
differences in the extent of binding reflected that previously
observed (Walker, 1984c).
The significance of the relationship between the extent of
reactivity for all markers and differentiation and node status
is shown in Table III. Only two of the 15 carcinomas having
many cells staining with HMFG1 were poorly differentiated
but no other relationship was seen with that antibody. For
NCRC 11 three quarters of the well differentiated tumours
had greater than 50% cells staining and 60% of the car-
cinomas with less than 50% of cells reacting were poorly
differentiated. Similar trends were observed for 140 Cl. None
of the other milk fat globule membrane antibody reactivities
showed any relationship with differentiation.
For the lectins, the binding of peanut agglutinin, wheat
germ agglutinin and Concanavalin A correlated with
differentiation, as noted previously (Walker, 1983, 1984a, b,
1985), while the binding of fucose-specific lectins did not.
The only marker to show any relationship to node status
was wheat germ agglutinin. Those tumours which showed
heterogeneous binding were more likley to have metastasised
than those which did not. Although overall Ulex europaeus I
binding did not relate to node status, carcinomas with
heterogeneous binding were less likely to have metastasised.
For all other markers the patterns of staining were evenly
distributed between the node negative and positive groups.
Relationship to recurrence and survival
The relationship of lymph node status and histological
differentiation to the development of recurrent disease and
survival was analysed, and the findings are shown in Table
IV. There was a significant association between histological
grade and morbidity and mortality (X2 = 8.82, 2 d.f.,
0.02>P>0.01; X2=8.87, 2 d.f., 0.02>P>0.01 respec-
tively), the major factors being in relation to well
differentiated carcinomas (Figure 1). There was no relation-
ship between node status and development of recurrent
Table III Relationship between extent of reactivity with milk fat
globule membrane antibodies and lectins and tumour grade and node
status
Marker Grade Node status
HMFGI N.S. N.S.
HMFG2 N.S. N.S.
NCRC 11 P<0.001 N.S.
115 D8 N.S. N.S.
115 Fl N.S. N.S.
139 H2 N.S. N.S.
140 CI 0.05>P>0.02 N.S.
PNA P<0.001 N.S.
WGA 0.01 >P>0.001 0.05>P>0.02
ConA P<0.001 N.S.
LTA N.S. N.S.
UEA N.S. N.S.
N.S. = not significant
Table IV Relationship between development ofrecurrent disease and
survival andlymph node status and histological differentiation (grade)
Freefrom disease Recurrence Alive Dead
Lymph node
Metastasis 34 21 39 16
Free from 44 16 51 9
metastasis
Grade
I 16 1 17 0
II 39 17 45 1 1
III 23 19 28 14
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Figure 1 Actuarial curve for overall survival in relation to
tumour differentiation (0.02>P>0.01). I = well differentiated,
II = moderately differentiated, III = poorly differentiated.
disease, and only a weak association with survival (x2= 3.27,
0.01 >P>0.05).
The relationship between the pattern of staining for each
marker and recurrence and survival was assessed. For the
milk fat globule membrane antibodies only one, NCRC 11,
showed a significant relationship with both survival (x2 = 7.8,
3 d.f., 0.05>P>0.02) and recurrence (x2 = 7.96, 3 d.f.,
0.05>P>0.02) (Table V; Figure 2). No relationships were
identified for any of the lectins.
Cox's proportional hazards regression model was then
fitted to the data. To allow the major assumption for the
model (proportionality of hazards for each level of variable)
to be fulfilled, grade was used to stratify the data. When the
other variables were entered into the model no significant
associations were found with morbidity or mortality. Hence,
the relationship between NCRC 11 staining patterns and
recurrence and survival is not independent of that shown for
histological grade.
Table V Relationship between staining patterns with NCRC 11 and
development of recurrent disease and survival
Staining category NCRC 11
<25 25-50 50-75 > 75
Free from recurrent 13 4 32 30
disease
Recurrence 12 5 10 9
Alive 16 5 35 34
Dead 9 4 7 5
Figure 2 Actuarial curve for overall survival in relation to stain-
ing with NCRC 11, 50% of cells positive being the cut-off point
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Discussion
Several studies have been reported which assess the value of
using monoclonal antibodies and lectin binding to determine
the behaviour of breast carcinomas (Wilkinson et al., 1984;
Berry et al., 1985; Rasmussen et al., 1985; Ellis et al., 1987;
Fenlon et al., 1987; Leatham & Brooks, 1987). The present
study differs in applying a wide range of markers to the same
group of early breast carcinomas and has found that the
majority show no relationship to patient outcome and that
the one that does is not an independent predictor.
The number included in the study are smaller than some
series e.g. that of Ellis et al. (1987) but are comparable to
others (Berry et al., 1985). The period of follow-up is also
shorter than that of Ellis et al. (1987) but is similar to other
studies. Receptor status data, considered by several groups,
was not available for all tumours, so was not included.
Node status was not as prognostically significant as would
be expected (Fisher et al., 1975; Blamey et al., 1979). This
may be due to the shorter period of follow-up than that
considered in other studies. Histological grading proved to be
of prognostic value, as reported by others (Elston et al.,
1982; Contesso et al., 1989).
Previous assessments of the milk fat globule membrane
antibodies HMFGI and HMFG2 have differed in their con-
clusions. Wilkinson et al. (1984) considered that the localisa-
tion as well as the extent of staining with HMFGI was
important as a prognostic indicator. This was not included in
the categorisation of staining patterns in the present study
but was by Berry et al. (1985), yet neither study found a
relationship between HMFGI and prognosis. The antigen
recognised by HMFGI has a relationship to functional
differentiation in that tumours with >20% of cells express-
ing it are more likely to respond to endocrine therapy (Bail-
dam et al., 1988) and contain oestrogen and progesterone
receptor (Baildam et al., 1989). While no significant relation-
ship to structural differentiation was recognised in the pres-
ent study, this may be due to different cut-off points for
extent of expression. HMFG2 staining patterns are again
shown to be of no prognostic value.
The only marker which showed any relationship to
development of recurrent disease and survival was NCRC 11,
when assessed by life table analysis, which concurs with the
findings of Ellis et al. (1987) but not those of Angus et al.
(1986). However, multivariate analysis showed that in this
series it did not act as an independent prognostic indicator,
as previously reported, because of the close relationship
between staining and histological grade. The latter relation-
ship has also been shown by Ellis et al. Rasmussen et al.
(1985) noted that staining with the milk fat globule mem-
brane antibody Mam 3b gave prognostic information but
that there was no improvement in prediction of recurrence
over that given by standard methods. As indicated above, the
duration of follow-up in the present study is shorter than the
study of Ellis et al. It will be of interest to see whether there
is any change in the significance of NCRC 11 as a predictor
when the patients are followed for a longer time period.
The series of antibodies directed against Mam 6 have not
previously been evaluated for prognostic value but none
showed any relationship. This group of antibodies (Hilkens
et al., 1984) like HMFG1 and 2 (Taylor-Papadimitriou et al.,
1981) were raised against the milk fat globule membrane,
whereas NCRC 11 was generated against a membrane frac-
tion of a breast carcinoma metastasis (Ellis et al., 1984). All
detect antigenic sites on polymorphic epithelial nuclei (PEM)
(Hilkens, 1988). The differences in the frequency of staining
patterns within and between carcinomas, and in their rela-
tionships to differentiation and behaviour, reflect the complex
glycosylated nature and the physical structure of PEM. It is
of interest that NCRC 11 should behave differently from the
other antibodies since it detects glycoproteins of a similar
molecular weight to other milk fat globule membrane
antibodies (Griffiths et al., 1987).
Lectins bind to specific sugar groups, but these can be
common to several glycoproteins present within the same cell
or tissue. Other problems in using and interpreting lectin
binding is that minor variations in the composition of
oligosaccharide chains, not necessarily involving the lectin-
specific sugars, can affect binding. Such micro-heterogeneity
is more frequent in carcinomas (Ogata et al., 1976). It is
therefore not surprising that lectin binding has not proved to
be of short-term prognostic value. Fenlon et al. (1987) con-
sidered Ulex europaeus I staining to relate to disease-free
interval and survival but studied patients with a longer
period of follow-up. Leatham & Brooks (1987) found Helix
pomatia binding to be of predictive value in premenopausal
but not post-menopausal women. Evaluation of a larger
series than the present one would be required to confirm or
refute their findings.
The assessment of histological grade has been criticised
because of its subjective nature (Stenkvist et al., 1979). There
can also be many problems in using immunohistochemistry
as a prognostic tool. Factors which can effect findings and
make comparability between laboratories difficult are: the
effect of fixation; the sensitivity of the methods used; and the
methods of assessment of staining. From this study of
markers in relation to short-term prognosis none have been
found which can give independent prognostic information
over and above that which can be obtained from a
haematoxylin and eosin stained section. Evaluation of the
data after a longer period of follow-up will be of interest to
assess whether the same conclusion applies.
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